Welcome to our dedicated page for Sanuwave Health news (Ticker: SNWV), a resource for investors and traders seeking the latest updates and insights on Sanuwave Health stock.
SANUWAVE Health, Inc. reports company developments tied to FDA-cleared and FDA-approved directed-energy systems used in advanced wound care. The company researches, develops and commercializes non-invasive regenerative medicine technologies designed to activate biological responses for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. Its wound care portfolio includes the UltraMIST product line and related product candidates.
Recurring news includes quarterly and annual revenue updates, financial guidance, conference-call materials, medical-device commercialization activity and channel relationships for UltraMIST. Company updates also describe applications of its energy transfer technologies in wound healing, orthopedic and spine, aesthetic and cosmetic, and cardiac and endovascular conditions.
SANUWAVE Health (OTCQB: SNWV) announced its participation in the 37th Annual Roth Conference, scheduled for March 16-18, 2025, at the Laguna Cliffs Marriott Resort & Spa in Dana Point, California. CEO Morgan Frank will be available for one-on-one meetings with investors throughout the conference.
The Annual Roth Conference is one of the nation's largest small-cap company events, featuring approximately 500 private and public companies from various growth sectors. The conference format includes company presentations, Q&A sessions, and management meetings, covering sectors such as consumer, healthcare, industrial growth, sustainability, and technology.
SANUWAVE Health specializes in non-invasive medical systems for skin, musculoskeletal tissue, and vascular structure regeneration. The company's wound care portfolio utilizes patented energy transfer technologies to support natural healing processes across wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular applications.
SANUWAVE Health reported record Q3 2024 financial results with revenues of $9.4 million, up 89% from Q3 2023. The company achieved a gross margin of 75.5% and GAAP Operating Income of $2.0 million. UltraMist® system sales increased to 124 units in Q3 2024, up from 55 in Q3 2023, while consumables revenue grew 75% to $5.4 million. Despite operational improvements, the company reported a net loss of $20.7 million, primarily due to derivative liabilities. SANUWAVE provides guidance for Q4 2024 revenue growth of 40-50% versus Q4 2023, projecting full-year 2024 revenues to exceed $32 million.
SANUWAVE Health (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, announced it will host a conference call on November 8, 2024, at 8:30 AM (ET) to discuss its Q3 2024 financial results. Participants can join via toll-free number 1-800-267-6316 or international number 1-203-518-9783 using Conference ID: SANUWAVE. Materials will be available on the company's website, and a replay will be accessible through November 29, 2024, using replay access ID: 11157276.
SANUWAVE Health announced a 1-for-375 reverse stock split effective from October 18, 2024. The common stock will trade on a split-adjusted basis under the symbol SNWV on the OTCQB, with a new CUSIP number, 80303D 305. This move will reduce the outstanding shares from approximately 1.18 billion to 3.15 million. Proportional adjustments will be made to equity awards, convertible notes, and warrants. No fractional shares will be issued; instead, fractional shares will be settled in cash. The reverse stock split will not change the total number of authorized shares or alter any stockholder's percentage interest in the company, except for adjustments due to fractional shares. Stockholders will receive transaction statements and information from the Securities Transfer regarding the exchange process.
SANUWAVE Health (OTCQB: SNWV) reported record quarterly revenues for Q2 FY2024. Key highlights include:
- Q2 2024 revenues of $7.2 million, up 53% year-over-year
- Gross margin of 73%, slightly down from 74% in Q2 2023
- GAAP Operating Income of $2.0 million
- Net income of $6.6 million, compared to a net loss of $7.3 million in Q2 2023
- Adjusted EBITDA of $1.5 million, up from $171,000 in Q2 2023
- 72 UltraMist® systems sold, up from 49 in Q2 2023
- UltraMist® consumables revenue increased by 67% to $4.7 million
The company provided guidance for Q3 2024, expecting revenue growth of 65-75% compared to Q3 2023. SANUWAVE also secured approval for a reverse stock split and 100% participation in its note and warrant exchange offer.
SANUWAVE Health, Inc. (OTCQB: SNWV), a leading provider of FDA-approved wound care products, has announced a live conference call scheduled for August 13, 2024, at 8:30 AM (ET) to present their Q2 2024 financial results. Investors can access the call via toll-free (1-800-579-2543) or international (1-785-424-1789) numbers using the Conference ID: SANUWAVE. Alternatively, instant telephone access is available through a provided link.
Conference materials will be accessible on the company's website. A replay of the call will be available until September 3, 2024, using specific replay access numbers and ID. This event provides an opportunity for stakeholders to gain insights into SANUWAVE's recent financial performance and future outlook.
Summary not available.
Summary not available.
Summary not available.
Summary not available.